Skip to main content
Erschienen in: Updates in Surgery 2/2017

28.04.2017 | Review Article

Surgical approaches in hereditary endocrine tumors

verfasst von: Maurizio Iacobone, Marilisa Citton, Giovanni Viel, Donatella Schiavone, Francesca Torresan

Erschienen in: Updates in Surgery | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Endocrine tumors of thyroid, adrenal and parathyroid glands may be due to germline and inheritable mutations in 5–30% of patients. Medullary Thyroid Carcinoma, Pheochromocytoma, Paraganglioma, and Familial Primary Hyperparathyroidism are the most frequent entity. Hereditary endocrine tumors usually have a suggestive familial history; they occur earlier than sporadic variants, are multifocal, and have increased recurrence rates. They may be present as isolated variant or associated to other neoplasms in a syndromic setting. Genetic diagnosis should be preferably available before surgery because specific and targeted operative management are needed to achieve the best chance of cure. This review was aimed to discuss the surgical approaches for some of the most frequent hereditary endocrine tumors of thyroid, adrenal and parathyroid glands, focusing on medullary thyroid carcinoma, Pheochromocytoma, Paraganglioma and hereditary primary hyperparathyroidism (pHPT). Hereditary Medullary Thyroid Carcinoma is caused by RET mutations, and may be associated to Pheochromocytomas in MEN 2 setting. Total thyroidectomy and at least central neck nodal dissection is required. The availability of genetic screening allows prophylactic or early surgery in asymptomatic patients, with subsequent definitive cure. Hereditary Pheochromocytomas may be present in several syndromes (MEN 2, VHL, NF1, Paraganglioma/Pheochromocytoma syndrome); it may involve both adrenals; in these cases, a cortical sparing adrenalectomy should be performed to avoid permanent hypocorticosurrenalism. Hereditary Primary Hyperparathyroidism may frequently occur associated to MEN 1, MEN 2A, MEN 4, Hyperparathyroidism-Jaw Tumor Syndrome; it may involve all the parathyroid glands, requiring subtotal parathyroidectomy or total parathyroidectomy plus autotransplantation. In some cases, a selective parathyroidectomy might be performed.
Literatur
1.
Zurück zum Zitat Iacobone M, Carnaille B, Palazzo FF, Vriens M (2015) Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 400:867–886CrossRefPubMed Iacobone M, Carnaille B, Palazzo FF, Vriens M (2015) Hereditary hyperparathyroidism—a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg 400:867–886CrossRefPubMed
2.
Zurück zum Zitat Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA Jr, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ (2010) Medullary carcinoma. J Natl Compr Canc Netw 8:512–530CrossRefPubMed Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA Jr, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ (2010) Medullary carcinoma. J Natl Compr Canc Netw 8:512–530CrossRefPubMed
3.
Zurück zum Zitat Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671CrossRefPubMed Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells SA Jr, Marx SJ (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671CrossRefPubMed
4.
Zurück zum Zitat Wells SA, Asa SL, Dralle H, Elisei R et al (2015) Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610CrossRefPubMedPubMedCentral Wells SA, Asa SL, Dralle H, Elisei R et al (2015) Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma. Thyroid 25(6):567–610CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. EJSO 33:493–497CrossRefPubMed Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D (2007) Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. EJSO 33:493–497CrossRefPubMed
6.
Zurück zum Zitat Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol 22:475–485CrossRef Pacini F, Castagna MG, Cipri C, Schlumberger M (2010) Medullary thyroid carcinoma. Clin Oncol 22:475–485CrossRef
7.
Zurück zum Zitat Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2655–2663CrossRefPubMed Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab 95(6):2655–2663CrossRefPubMed
8.
Zurück zum Zitat Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB (2003) Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134:946–955CrossRefPubMed Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB (2003) Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 134:946–955CrossRefPubMed
9.
Zurück zum Zitat Machens A, Dralle H (2007) Genotype–phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 31:957–968CrossRefPubMed Machens A, Dralle H (2007) Genotype–phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 31:957–968CrossRefPubMed
10.
Zurück zum Zitat Pelizzo MR, Torresan F, Boschin IM, Nacamulli D, Pennelli G, Barollo S, Rubello D, Mian C (2015) Early, prophylactic thyroidectomy in hereditary medullary thyroid carcinoma: a 26-year monoinstitutional experience. Am J Clin Oncol 38:508–513CrossRefPubMed Pelizzo MR, Torresan F, Boschin IM, Nacamulli D, Pennelli G, Barollo S, Rubello D, Mian C (2015) Early, prophylactic thyroidectomy in hereditary medullary thyroid carcinoma: a 26-year monoinstitutional experience. Am J Clin Oncol 38:508–513CrossRefPubMed
11.
12.
Zurück zum Zitat Shober A, Parlato R, Huber K, Kinscherf R, Hartleben B, Huber TB, Schutz G, Unsicker K (2013) Cell loss and autophagy in the extra-adrenal chromaffin organ of Zuckerkandl are regulated by glucorticoid signalling. J Neuroendocrinol 25:34–47CrossRef Shober A, Parlato R, Huber K, Kinscherf R, Hartleben B, Huber TB, Schutz G, Unsicker K (2013) Cell loss and autophagy in the extra-adrenal chromaffin organ of Zuckerkandl are regulated by glucorticoid signalling. J Neuroendocrinol 25:34–47CrossRef
13.
Zurück zum Zitat van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP et al (2010) Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab 95:209–214CrossRefPubMed van Duinen N, Steenvoorden D, Kema IP, Jansen JC, Vriends AH, Bayley JP et al (2010) Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas. J Clin Endocrinol Metab 95:209–214CrossRefPubMed
14.
Zurück zum Zitat Dahia PL (2014) Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 14:108–119CrossRefPubMed Dahia PL (2014) Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer 14:108–119CrossRefPubMed
15.
Zurück zum Zitat Iacobone M, Schiavi F, Bottussi M, Taschin E, Bobisse S, Fassina A, Opocher G, Favia G (2011) Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas? Surgery 150(6):1194–1201CrossRefPubMed Iacobone M, Schiavi F, Bottussi M, Taschin E, Bobisse S, Fassina A, Opocher G, Favia G (2011) Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas? Surgery 150(6):1194–1201CrossRefPubMed
16.
Zurück zum Zitat Opocher G, Schiavi F, Iacobone M, Toniato A, Sattarova S, Erlic Z, Martella M, Mian C, Merante Boschin I, Zambonin L, De Lazzari P, Murgia A, Pelizzo MR, Favia G, Mantero F (2006) Familial nonsyndromic pheochromocytoma. Ann N Y Acad Sci 1073:149–155CrossRefPubMed Opocher G, Schiavi F, Iacobone M, Toniato A, Sattarova S, Erlic Z, Martella M, Mian C, Merante Boschin I, Zambonin L, De Lazzari P, Murgia A, Pelizzo MR, Favia G, Mantero F (2006) Familial nonsyndromic pheochromocytoma. Ann N Y Acad Sci 1073:149–155CrossRefPubMed
17.
Zurück zum Zitat Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacchè M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M, Dahia PL (2010) Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 304(23):2611–2619CrossRefPubMed Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, Mori L, Giacchè M, Mendola A, Taschin E, Boaretto F, Loli P, Iacobone M, Rossi GP, Biondi B, Lima-Junior JV, Kater CE, Bex M, Vikkula M, Grossman AB, Gruber SB, Barontini M, Persu A, Castellano M, Toledo SP, Maher ER, Mannelli M, Opocher G, Robledo M, Dahia PL (2010) Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 304(23):2611–2619CrossRefPubMed
18.
Zurück zum Zitat Williamson SR, Eble JN, Amin MB, Gupta NS, Smith SC, Sholl LM, Montironi R, Hirsch MS, Hornick JL (2015) Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol 28:80–94CrossRefPubMed Williamson SR, Eble JN, Amin MB, Gupta NS, Smith SC, Sholl LM, Montironi R, Hirsch MS, Hornick JL (2015) Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol 28:80–94CrossRefPubMed
19.
Zurück zum Zitat Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D (2015) Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer 22:T135–T145CrossRefPubMed Castinetti F, Kroiss A, Kumar R, Pacak K, Taieb D (2015) Imaging and imaging-based treatment of pheochromocytoma and paraganglioma. Endocr Relat Cancer 22:T135–T145CrossRefPubMed
20.
Zurück zum Zitat Welander J, Söderkvist P, Gimm O (2011) Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 18(6):R253–R276CrossRefPubMed Welander J, Söderkvist P, Gimm O (2011) Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr Relat Cancer 18(6):R253–R276CrossRefPubMed
21.
Zurück zum Zitat Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT et al (1990) Clinical features and natural history of von Hippel–Lindau disease. Q J Med 77(283):1151–1163CrossRefPubMed Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT et al (1990) Clinical features and natural history of von Hippel–Lindau disease. Q J Med 77(283):1151–1163CrossRefPubMed
22.
Zurück zum Zitat Woodward ER, Buchberger A, Clifford SC, Hurst LD, Affara NA, Maher ER (2000) Comparative sequence analysis of the VHL suppressor gene. Genomics 65(3):253–265CrossRefPubMed Woodward ER, Buchberger A, Clifford SC, Hurst LD, Affara NA, Maher ER (2000) Comparative sequence analysis of the VHL suppressor gene. Genomics 65(3):253–265CrossRefPubMed
23.
Zurück zum Zitat Opocher G, Schiavi F (2010) Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 24:943–956CrossRefPubMed Opocher G, Schiavi F (2010) Genetics of pheochromocytomas and paragangliomas. Best Pract Res Clin Endocrinol Metab 24:943–956CrossRefPubMed
24.
Zurück zum Zitat Stratakis CA (2009) New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors. Mol Cell Endocrinol 300:152–157CrossRefPubMed Stratakis CA (2009) New genes and/or molecular pathways associated with adrenal hyperplasias and related adrenocortical tumors. Mol Cell Endocrinol 300:152–157CrossRefPubMed
25.
Zurück zum Zitat Haller F, Moskalev EA, Faucz FR, Barthelmeß S, Wiemann S, Bieg M, Assie G, Bertherat J, Schaefer IM, Otto C, Rattenberry E, Maher ER, Ströbel P, Werner M, Carney JA, Hartmann A, Stratakis CA, Agaimy A (2014) Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 21:567–577CrossRefPubMedPubMedCentral Haller F, Moskalev EA, Faucz FR, Barthelmeß S, Wiemann S, Bieg M, Assie G, Bertherat J, Schaefer IM, Otto C, Rattenberry E, Maher ER, Ströbel P, Werner M, Carney JA, Hartmann A, Stratakis CA, Agaimy A (2014) Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 21:567–577CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Asari R, Scheuba C, Kaczirek K, Niederle B (2006) Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg 141:1199–1205CrossRefPubMed Asari R, Scheuba C, Kaczirek K, Niederle B (2006) Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg 141:1199–1205CrossRefPubMed
27.
Zurück zum Zitat Walz MK (2004) Extent of adrenalectomy for adrenal neoplasm: cortical sparing (subtotal) versus total adrenalectomy. Surg Clin N Am 84:743–753CrossRefPubMed Walz MK (2004) Extent of adrenalectomy for adrenal neoplasm: cortical sparing (subtotal) versus total adrenalectomy. Surg Clin N Am 84:743–753CrossRefPubMed
28.
Zurück zum Zitat Brauckhoff M, Nguyen TP, Bar A, Dralle H (2003) Subtotal bilateral adrenalectomy preserving adrenocortical function. Chirurg 74(7):646–651CrossRefPubMed Brauckhoff M, Nguyen TP, Bar A, Dralle H (2003) Subtotal bilateral adrenalectomy preserving adrenocortical function. Chirurg 74(7):646–651CrossRefPubMed
29.
Zurück zum Zitat Hahner S, Hemmelmann N, Quinkler M, Beuschlein F, Spinnler C, Allolio B (2015) Timelines in the management of adrenal crisis—targets, limits and reality. Clin Endocrinol 82:497–502CrossRef Hahner S, Hemmelmann N, Quinkler M, Beuschlein F, Spinnler C, Allolio B (2015) Timelines in the management of adrenal crisis—targets, limits and reality. Clin Endocrinol 82:497–502CrossRef
30.
Zurück zum Zitat Okamato T, Obara T, Ito Y et al (1996) Bilateral adrenalectomy with autotransplantation of adrenalcortical tissue or unilateral adrenalectomy: treatment options for pheochromocytoma in multiple endocrine neoplasia type 2A. Endocr J 43:169–175CrossRef Okamato T, Obara T, Ito Y et al (1996) Bilateral adrenalectomy with autotransplantation of adrenalcortical tissue or unilateral adrenalectomy: treatment options for pheochromocytoma in multiple endocrine neoplasia type 2A. Endocr J 43:169–175CrossRef
31.
Zurück zum Zitat Demeter JG, De Jong SA, Brooks MH, Lawrence AM, Paloyan E (1990) Long-term results of adrenal autotransplantation in Cushing’s disease. Surgery 108:1117–1123PubMed Demeter JG, De Jong SA, Brooks MH, Lawrence AM, Paloyan E (1990) Long-term results of adrenal autotransplantation in Cushing’s disease. Surgery 108:1117–1123PubMed
32.
Zurück zum Zitat Inabnet WB, Caragliano P, Pertsemlidis D (2000) Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery 128:1007–1012CrossRefPubMed Inabnet WB, Caragliano P, Pertsemlidis D (2000) Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. Surgery 128:1007–1012CrossRefPubMed
33.
Zurück zum Zitat Hardy JD, Moore DO, Langford HG (1985) Cushing’s disease today: late follow-up of 17 adrenalectomy patients with emphasis on eight with adrenal autotransplants. Ann Surg 201:595–603CrossRefPubMedPubMedCentral Hardy JD, Moore DO, Langford HG (1985) Cushing’s disease today: late follow-up of 17 adrenalectomy patients with emphasis on eight with adrenal autotransplants. Ann Surg 201:595–603CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Koch CA, Pacak K, Chrousos GP (2002) The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87:5367–5384CrossRefPubMed Koch CA, Pacak K, Chrousos GP (2002) The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 87:5367–5384CrossRefPubMed
35.
Zurück zum Zitat Alesina PF, Hinrichs J, Meier B, Schmid KW, Neumann HP, Walz MK (2012) Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas. Langenbeck Arch Surg 397:233–238CrossRef Alesina PF, Hinrichs J, Meier B, Schmid KW, Neumann HP, Walz MK (2012) Minimally invasive cortical-sparing surgery for bilateral pheochromocytomas. Langenbeck Arch Surg 397:233–238CrossRef
36.
Zurück zum Zitat Castinetti F, Qi XP, Walz MK, Maia AL, Sanso G, Peczkowska M, Hasse-Lazar K, Links TP, Dvorakova S, Toledo RA et al (2014) Outcomes of adrenal-sparing surgery or total adrenalectomy in pheochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol 15:648–655CrossRefPubMed Castinetti F, Qi XP, Walz MK, Maia AL, Sanso G, Peczkowska M, Hasse-Lazar K, Links TP, Dvorakova S, Toledo RA et al (2014) Outcomes of adrenal-sparing surgery or total adrenalectomy in pheochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol 15:648–655CrossRefPubMed
37.
Zurück zum Zitat Castinetti F, Taieb D, Henry JF, Walz M, Guerin C, Brue T, Conte-Devolx B, Neumann HPH, Sebag F (2016) Management of endocrine disease: outcome of adrenal sparing surgery in heritable pheochromocytoma. Eur J Endocrinol 174:R9–R18CrossRefPubMed Castinetti F, Taieb D, Henry JF, Walz M, Guerin C, Brue T, Conte-Devolx B, Neumann HPH, Sebag F (2016) Management of endocrine disease: outcome of adrenal sparing surgery in heritable pheochromocytoma. Eur J Endocrinol 174:R9–R18CrossRefPubMed
38.
Zurück zum Zitat Grubbs EG, Rich TA, Ng C, Bhosale PR, Jimenez C, Evans DB, Lee JE, Perrier ND (2013) Long term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 216:280–289CrossRefPubMed Grubbs EG, Rich TA, Ng C, Bhosale PR, Jimenez C, Evans DB, Lee JE, Perrier ND (2013) Long term outcomes of surgical treatment for hereditary pheochromocytoma. J Am Coll Surg 216:280–289CrossRefPubMed
39.
Zurück zum Zitat Hsu SC, Levine MA (2002) Primary hyperparathyroidism in children and young adult: the Johns Hopkins Children’s Center experience 1984–2001. J Bone Miner Res 17:N44–N50PubMed Hsu SC, Levine MA (2002) Primary hyperparathyroidism in children and young adult: the Johns Hopkins Children’s Center experience 1984–2001. J Bone Miner Res 17:N44–N50PubMed
40.
Zurück zum Zitat Sneider MS, Solorzano CC, Montano RE et al (2009) Sporadic primary hyperparathyroidism in young individuals: different disease and treatment? J Surg Res 155:100–103CrossRefPubMed Sneider MS, Solorzano CC, Montano RE et al (2009) Sporadic primary hyperparathyroidism in young individuals: different disease and treatment? J Surg Res 155:100–103CrossRefPubMed
41.
Zurück zum Zitat Giusti F, Cavalli L, Cavalli T, Brandi ML (2013) Hereditary hyperparathyroidism syndromes. J Clin Densitom 16:69–74CrossRefPubMed Giusti F, Cavalli L, Cavalli T, Brandi ML (2013) Hereditary hyperparathyroidism syndromes. J Clin Densitom 16:69–74CrossRefPubMed
42.
Zurück zum Zitat Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN 1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29:22–32CrossRefPubMed Lemos MC, Thakker RV (2008) Multiple endocrine neoplasia type 1 (MEN 1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29:22–32CrossRefPubMed
43.
Zurück zum Zitat Iacobone M, Ruffolo C, Lumachi F, Favia G (2005) Results of iterative surgery for persistent and recurrent parathyroid carcinoma. Langenbecks Arch Surg 390(5):385–390CrossRefPubMed Iacobone M, Ruffolo C, Lumachi F, Favia G (2005) Results of iterative surgery for persistent and recurrent parathyroid carcinoma. Langenbecks Arch Surg 390(5):385–390CrossRefPubMed
44.
Zurück zum Zitat Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML (2009) Surgical approach in hereditary hyperparathyroidism. Endocr J 56:827–841CrossRefPubMed Tonelli F, Marcucci T, Giudici F, Falchetti A, Brandi ML (2009) Surgical approach in hereditary hyperparathyroidism. Endocr J 56:827–841CrossRefPubMed
45.
Zurück zum Zitat Udelsman R, Akerström G, Biagini C, Duh QY, Miccoli P, Niederle B, Tonelli F (2014) The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99:3595–3606CrossRefPubMed Udelsman R, Akerström G, Biagini C, Duh QY, Miccoli P, Niederle B, Tonelli F (2014) The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab 99:3595–3606CrossRefPubMed
46.
Zurück zum Zitat Carling T, Udelsman R (2005) Parathyroid surgery in familial hyperparathyroidism disorders. J Intern Med 257:27–37CrossRefPubMed Carling T, Udelsman R (2005) Parathyroid surgery in familial hyperparathyroidism disorders. J Intern Med 257:27–37CrossRefPubMed
47.
Zurück zum Zitat Fritz A, Walch A, Piotrowska K et al (2002) Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 62:3048–3051PubMed Fritz A, Walch A, Piotrowska K et al (2002) Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res 62:3048–3051PubMed
48.
Zurück zum Zitat Pellagata NS, Quintanilla-Martinez L, Siggelkow H et al (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103:15558–15563CrossRef Pellagata NS, Quintanilla-Martinez L, Siggelkow H et al (2006) Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 103:15558–15563CrossRef
49.
Zurück zum Zitat Iacobone M, Masi G, Barzon L, Porzionato A, Macchi V, Ciarleglio FA, Palù G, De Caro R, Viel G, Favia G (2009) Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg 394(5):817–825CrossRefPubMed Iacobone M, Masi G, Barzon L, Porzionato A, Macchi V, Ciarleglio FA, Palù G, De Caro R, Viel G, Favia G (2009) Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg 394(5):817–825CrossRefPubMed
50.
Zurück zum Zitat Iacobone M, Barzon L, Porzionato A, Masi G, Macchi V, Viel G, Favia G (2009) The extent of parathyroidectomy for HRPT2-related hyperparathyroidism. Surgery 145(2):250–251CrossRefPubMed Iacobone M, Barzon L, Porzionato A, Masi G, Macchi V, Viel G, Favia G (2009) The extent of parathyroidectomy for HRPT2-related hyperparathyroidism. Surgery 145(2):250–251CrossRefPubMed
Metadaten
Titel
Surgical approaches in hereditary endocrine tumors
verfasst von
Maurizio Iacobone
Marilisa Citton
Giovanni Viel
Donatella Schiavone
Francesca Torresan
Publikationsdatum
28.04.2017
Verlag
Springer Milan
Erschienen in
Updates in Surgery / Ausgabe 2/2017
Print ISSN: 2038-131X
Elektronische ISSN: 2038-3312
DOI
https://doi.org/10.1007/s13304-017-0451-y

Weitere Artikel der Ausgabe 2/2017

Updates in Surgery 2/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.